John Rex

John Rex ­JPMorgan SECOND TEAM Joshua Raskin Barclays THIRD TEAM Model Portfolios to Deliver Alternative Asset Exposure Sponsored by BlackRock April 29, 2025 Charles Boorady ­Citi RUNNERS-UP Matthew Borsch Goldman Sachs ; Justin Lake UBS

John Rex joined ­­JPMorgan Securities in June, when it absorbed Bear, Stearns & Co., and “did not miss a beat — he stays at the top of his game,” says one ­money man­ager. Rex, 46, also remains at the top of his sector, a position he holds for a fifth year running. After having been bullish on the companies he covers for the past ­seven years, the analyst down­graded them to under­perform in March, reasoning that rising costs would cut ­into profits. By mid-­September, Health Net of Woodland Hills, California, had fallen 23.5 percent, United­Health Group of Minnetonka, Minnesota, had tumbled 22.5 percent, and Bethesda, Maryland’s Coventry Health Care was down 15.9 percent. Overall the sector slipped 7.7 percent during the period. In second for a fourth straight year, Joshua Raskin told clients in January to buy HealthSpring of Nashville, Tennessee, calling shares of the Medicare-­oriented HMO undervalued at $18.96. The stock price had risen to $21.05 by mid-­September — “a great call, leveraging his previous work on Medicare,” says one happy investor. Raskin ­moved to Barclays Capital after its parent ac­quired Lehman Brothers last month. Clients say Charles ­Boorady of ­Citi, in third place for a fourth straight year, goes “as far off the beaten path as necessary” to generate “solid ideas.” Boorady upgraded Medco­Health Solutions in April, saying shares of the Franklin Lakes, New Jersey–based pharmacy benefits man­ager were a bargain at $43.76. By mid-­September the stock had shot up 15.6 percent, to $50.60.

Return to The Best Analysts of the Year

Return to Rankings